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Introduction
Although the incidence and mortality of gastric cancer 
have decreased, gastric cancer remains an important health 
problem worldwide and is the most important malignancy 
in East Asia, including China, Japan, and Korea. According 
to GLOBOCAN 2012, 952,000 patients were newly 
diagnosed with gastric cancer (6.8% of total cancer and the 
fifth most common malignancy), and 723,000 died because 
of it (8.8% of the total cause of cancer death and the third 
most common cause) (1). 
 Although recent studies have established the role of 
chemotherapy and radiation therapy in gastric cancer (2-7), 
the most important strategy against gastric cancer remains 
surgery (8). Because surgery provides the only chance 
of a cure in patients with gastric cancer, qualified radical 
gastrectomy with lymph node dissection is very important 
for a better outcome. Through long debates regarding the 
optimal extent of lymph node dissection in gastric cancer 
surgery, D2 lymph node dissection is now recommended 
as standard treatment under the Japanese guidelines (9), 
the National Comprehensive Cancer Network (NCCN), 
and the European Society for Medical Oncology (ESMO) 
guidelines when it can be performed safely (10,11). D2 
lymph node dissection in total gastrectomy for upper body 
gastric cancer includes spleen hilar lymph node dissection 
[#11d and #10 according to the Japanese guidelines (9)], and 
dissecting these areas appropriately and safely is one of the 
technical challenges even in open surgery for gastric cancer 
because the anatomy of the vessels in these areas is very 
complicated. 
Several decades ago, distal pancreatectomy and 
splenectomy were usually performed to dissect lymph 
nodes around #11d and #10 areas, sometimes leading to 
more complications such as pancreatic leak and subphrenic 
abscess (12). In 1970s’, Maruyama et al. (13) performed and 
reported pancreas-preserving total gastrectomy for gastric 
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cancer with reasonable morbidity and mortality. Noh et al. 
presented the technical possibility of spleen-preserving 
total gastrectomy with complete dissection of splenic hilar 
lymph nodes using an electrocautery device (Bovie) for 
the first time at the second International Gastric Cancer 
Congress (IGCC) which was held at 1997 in München, 
Germany. Additionally, several trials have reported the 
advantages of spleen-preserving and pancreas-preserving 
total gastrectomy; subgroup analysis of a randomized 
controlled trial showed the highest morbidity and worst 
prognosis of pancreatico-splenectomy compared with spleen 
and pancreas-preserving total gastrectomy (14), spleen-
preserving gastrectomy showed better short-term outcomes 
than and similar long-term outcomes to splenectomy when 
#11d and #10 are dissected adequately (15,16). Although 
some surgeons still believe that appropriate lymph 
node dissection of #11d and #10 are impossible without 
splenectomy, well-trained and experienced surgeons 
most likely can perform it safely with low morbidity and 
mortality (16). Presently, pancreatectomy or splenectomy 
for lymph node dissection is not a standard procedure for 
upper body gastric cancer (10), but appropriate D2 lymph 
node dissection, including that of #11d and #10, remains 
important in gastric cancer surgery. 
Because laparoscopic surgery has several short-term 
advantages over open gastrectomy for gastric cancer, such as 
less pain, a shorter hospital stay, and cosmetic benefits (17), it 
has been widely applied in early gastric cancer without 
evidence of lymph node metastasis, particularly in Korea 
and Japan. Technically, performing complete D2 lymph 
node dissection with laparoscopic devices was questionable; 
thus, it had been carefully applied to gastric cancer 
surgery only for early gastric cancer in which less than 
D2 lymph node dissection is allowed during the initial 
period of laparoscopic gastrectomy. Presently, owing 
to the development of laparoscopic devices, advanced 
knowledge of laparoscopic view, and accumulated technical 
experiences, many surgeons attempt to perform D2 lymph 
node dissection in laparoscopic gastrectomy. Consequently, 
experienced gastric cancer surgeons have tried to expand 
its indication into locally advanced gastric cancer, however, 
its oncologic safety remains controversial: it is difficult to 
maintain the oncologic principles of cancer surgery such 
as using the no-touch technique, not manipulating the 
cancer itself, and minimizing blood loss and the operative 
time with proper radical lymph node dissection in advanced 
gastric cancer. Although the recent multicenter, large-scale 
retrospective study from Korea showed that the long-term 
oncologic outcome of laparoscopic gastrectomy for gastric cancer 
was comparable to that of open gastrectomy (18), there is no 
strong evidence to date from a randomized controlled trial 
to confirm the latter finding. Before the start of the KLASS 
II trial, an ongoing, multicenter, randomized controlled 
trial comparing the outcomes of laparoscopic and open 
gastrectomy in advanced gastric cancer, many surgeons could 
not join the trial because of the inadequate quality of D2 
lymph node dissection in their video clip for laparoscopic 
gastrectomy. This fact seems to suggest the difficulty of 
adequate D2 lymph node dissection in laparoscopic surgery. 
Additionally, D2 lymph node dissection in laparoscopic 
total gastrectomy is more complicated than that in 
laparoscopic distal gastrectomy because D2 lymph node 
dissection in total gastrectomy includes the #11d and #10 
areas where adequate lymph node dissection is challenging, 
even in open surgery, and anastomosis is more difficult. 
Thus, laparoscopic total gastrectomy with D2 lymph node 
dissection is technically challenging, and only experienced 
laparoscopic gastric cancer surgeons should perform it 
safely. 
Developing a surgical technique is an important mission 
for surgeons, and these efforts should be continued. 
Additionally, sharing knowledge and educating and training 
young surgeons are very important duties for experienced and 
senior surgeons. Thus, the recent report by Huang et al. (19) is 
very timely: their stepwise explanation with video can guide 
other surgeons, particularly young ones, regarding how 
spleen hilar lymph node dissection with laparoscopic devices 
can be performed for upper-body gastric cancer. Although 
their method may be used generally during laparoscopic 
total gastrectomy with hilar lymph node dissection, they 
summarized the procedure in an easily comprehensive 
form. We would like to add the following comments to 
their procedure. As the authors mentioned, changing 
the position, left side up with the reverse Trendelenburg 
position, could be helpful to dissect #11d and #10 because 
the operative field is improved. Adding the information the 
exact location of each trocar and its size would be helpful 
to readers. Additionally, when using an energy device 
around vessels, the acting blade should not contact the 
vessels directly, and the activation time should be decreased 
because pseudo-aneurysm can occur, leading to disastrous 
consequences for patients (20).
Adapting and developing a new technique are important 
to all surgeons worldwide. However, these efforts should 
be based on scientific rationale with oncologic principles. 
Sometimes, minimally invasive surgery is considered only 
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minimally invasive to outline skin incisions, however, 
the quality of surgery may be poor with a very long 
operative time, much bleeding, and inadequate lymph node 
dissection. Surgeons should not be a technician, should be 
a philosopher. Surgeons should always consider a patient’s 
safety as the most important factor during surgery, and 
the pursuit of innovation should be based on honoring 
oncologic principles.
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